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Objectives. We studied the rate of thromboembolism in patients 
undergoing bioprosthetic replacement of the aortic or mitral 
valve, or both, at serial intervals after operation and the effects of 
anticoagulant or antiplatelet treatment and risk factors. 
Background. Thromboembolism appears to occur early after 
operation, but the incidence, timing and risk factors for throm- 
boembolism and the role, timing, adequacy, effectiveness, dura- 
tion and risk of anticoagulation and antiplatelet agents are 
uncertain. 
Methods. The rate of thromboembolism was studied at three 
time intervals after operation (1 to 10, 11 to 90 and >90 days) in 
816 patients who underwent bioprosthetic replacement of the aortic 
or mitral valve, or both, at the Mayo Clinic from January 1975 to 
December 1982. The effect of antithrombotic therapy (warfarin, 
aspirin or dipyridamole, alone or in combination) was evaluated. 
Results. Median follow-up of surviving patients was 8.6 years. 
The rate of thromboembolism (%/year) decreased significantly 
(p < 0.01) at each time interval after operation (1 to 10, 11 to 90 
and >90 days) for mitral valve replacement (55%, 10% and 
2.4%/year, respectively) and over the first time interval for aortic 
valve replacement (41%, 3.6% and 1.9%/year, respectively). During 
the first 10 days, 52% to 70% of prothrombin time ratios were low 
(<1.5 × control). Patients with mitral valve replacement who 
received anticoagulation had a lower rate of thromboembolism for 
the entire follow-up period (2.5%/year with vs. 3.9%/year without 
anticoagulation, p = 0.05). Of 112 patients with a first thrombo- 
embolic episode, permanent disability occurred in 38% and death 
in 4%. Risk factors for emboli were lack of anticoagulation, mitral 
valve location, history of thromboembolism and increasing age. 
Only 10% of aortic, 44% of mitral and 17% of double valve 
recipients had anticoagulation at the time of an event. Patients 
with bleeding episodes (2.3%/year) were older and usually under- 
went anticoagulation. Blood transfusions were required in 60 of 
111 patients (1.2%/year), and 13 patients (0.3%/year) died. 
Conclusions. Thromboembolic risk was especially high for 
aortic and mitral valve replacement for 90 days after operation, 
and overall was increased with lack of anticoagulation, mitral 
valve location, previous thromboembolism and increasing age. 
Anticoagulation reduced thromboemboli and appears to be indi- 
cated in all patients as early as possible for 3 months and 
thereafter in those with risk factors, but needs prospective t sting. 
(J Am Coll Cardio11995;25:1111-9) 
Prophylaxis for thromboembolism hould be based on patho- 
genesis and risk. The peak incidence occurs during the first 3 
months after valve surgery, probably reflecting the lack of 
endothelialization f the newly implanted prosthetic and bio- 
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logic materials (1-3). Although bioprosthetic valves are less 
thrombogenic than mechanical prostheses, the rate of throm- 
boembolic episodes also varies depending on anticoagulation 
status and position of the valve (2). Thromboembolic events 
are less frequent after aortic than mitral valve replacement (4). 
Unresolved issues include the timing and incidence of throm- 
boembolism, timing and targeting of anticoagulation, the role 
of antiplatelet agents and the effectiveness and optimal dura- 
tion of antithrombotic therapy after bioprosthetic valve re- 
placement (3,5). 
We studied the rate of thromboembolism in patients who 
had bioprosthetic replacement of the aortic or mitral valve, or 
both. This rate was divided into three time intervals after 
operation: 1 to 10, 11 to 90 and >90 days. The effect of 
anticoagulant or antiplatelet treatment and risk factors for 
thromboembolism and major bleeding were also studied. 
©1995 by the American Collcgc of Cardiolo~ 0735-1097/95/$9.50 
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Methods  
From January 1975 to December 1982, 816 patients under- 
went replacement of an aortic or mitral valve, or both, with 
bioprosthetic porcine or bovine pericardial valves at the Mayo 
Clinic. Aortic valves were replaced in 424 patients, mitral 
valves in 326 and both valves in 66. Bioprostheses u ed were 
Hancock (48%), Carpentier-Edwards (18%) and Ionescu- 
Shiley (34%). 
Anticoagulation and antiplatelet therapy. Patients who 
had anticoagulation received either intravenous heparin (at 
least 25,000 U/24 h) or warfarin. Anticoagulation was consid- 
ered to be adequate when prothrombin time ratios (prothrom- 
bin time/control time) were between 1.5 and 2.0 (using rabbit 
brain thromboplastin), which is equivalent to an international 
normalized ratio between 3.0 and 4.5. 
Definitions of thromboembolic and bleeding events, Throm- 
boembolism to the brain or retina was defined as a temporau or 
permanent eurologic deficit of sudden onset with focal motor 
weakness or visual deficit, unexplained by other findings. It was 
coded as minor or transient when the deficit lasted <24 h and 
there was a full recovery, and major or permanent when the 
neurologic deficit was persistent (>24 h) or the patient died. 
Neurologic deficits within the first 24 h after operation were 
excluded because they may have been caused by an air or 
cholesterol embolism. A peripheral embolism was diagnosed 
when there was a sudden onset of arterial occlusion in the 
extremities. A coronary embolism was defined as an acute 
myocardial infarction in a young patient (<40 years old) with 
documented normal coronary arteries and no risk factors. In 
general, acomputed tomographic s an confirmed the diagnosis 
of cerebral infarction, and peripheral emboli were confirmed 
at angiography or operation. Cerebral thromboembolism was 
not considered of cardiac origin in the presence of severe 
atherosclcrotic carotid disease, with abnormal carotid ultra- 
sound or oculoplethysmography or with arteriographic evi- 
dence of severe carotid stenosis (>75%). 
Bleeding events requiring admission to the hospital were 
recorded regardless of the patient's anticoagulation status. 
Follow-up. After hospital discharge, patients were followed 
up by their physicians who determined treatment and per- 
formed all the routine valuations. Questionnaires were sent to 
the patients and their primary physicians in 1983 and again in 
1988. The questionnaires included a functional evaluation of 
the patient, current medication and drugs discontinued since 
operation, occurrence of strokes or other thromboembolic 
events, bleeding complications and hospital admission for 
cardiac problems. All prothrombin times were requested from 
physicians for those patients taking anticoagulant agents. If a 
patient was admitted to another hospital, details of that 
admission were obtained with the patient's consent. If ques- 
tionnaires were returned unclaimed or incomplete, patients 
were contacted by telephone; when patients could not be 
reached or the information remained incomplete, the treating 
physician was contacted. Therefore, all questions were an- 
swered by either the patient or the treating physician, or both. 
Only prothrombin times sent by the treating physician were 
recorded; 15,604 prothrombin times were obtained, or an 
average of one every 6 weeks of follow-up for patients receiv- 
ing anticoagulation. Prothrombin times were obtained at least 
once in 83% of all patients taking anticoagulant agents. 
Statistical methods. The primary end points considered 
were thromboernbolic and bleeding events; patients were 
censored at death or at their last available follow-up date (6). 
Time-dependent Cox proportional hazards models were used 
to identify potential risk factors associated with thromboem- 
bolic and bleeding events. According to these models, the 
instantaneous ri k of an event at any time is proportional to an 
underlying function of time, with the proportionality factor 
depending on the current treatment status (anticoagulant 
agents, aspirin and dipyridamole) as well as other non-time- 
dependent covariates. 
Multivariate Cox models were developed with a forward 
stepwise procedure. The location of valve replacement (aortic 
or mitral, or both) was always included in the model. Patients 
were coded as either eceiving or not receiving treatment for 
each day they were at risk; all other covariates remained fixed 
as the values at time of operation. The covariates assessed in 
the model for thromboembolism were treatment s atus, pre- 
operative and postoperative atrial fibrillation, preoperative 
thromboembolic event, year of operation, type of valve, age, 
gender, New York Heart Association functional class, left 
atrial size and coronary artery disease (values of the last two 
variables were not available for all patients). Treatment s atus, 
age, gender and year of operation were evaluated as risk 
factors for bleeding events. 
Differences in the rates of thromboembolic and bleeding 
events between time periods (0 to 10, 11 to 90, and >90 days) 
were tested separately for each valve location, using an approx- 
imate test for Poisson random variables. The rate of events 
that occurred uring anticoagulation versus the rate in the 
absence of anticoagulation was tested using a Mantel-Haenszel 
test stratified by time periods. 
The log-rank test was used to assess differences between the 
Kaplan-Meier curves for valve location with respect to the end 
points of thromboembolic and bleeding events, death and 
cardiac death. 
Resu l ts  
Results are reported according to the guidelines of Mc- 
Goon (7). Follow-up information was obtained for 99.9% of 
the patients. Median follow-up of surviving patients was 8.6 
years; mean [_+SD] follow-up was 8.3 _+ 2.4 years (range 1.7 to 
13.2, median 7.9), 9.5 _+ 2.4 years (range 1.7 to 13.2, median 
9.9) and 8.1 _+ 2.7 years (range 0.03 to 13.3, median 7.7) for 
patients undergoing aortic or mitral valve replacement, or 
both, respectively. 
Clinical variables before and after operation are presented 
in Table 1. Fifty-nine percent of patients were between 60 and 
80 years old, and 5.5% were >80 years. Patients with aortic 
prostheses were older and had a higher incidence of coronary 
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Table 1. Preoperative and Postoperative Clinical Variables 
Valve Replacement 
Aortic Mitral Aortic and Mitral 
(n 424) (n - 326) (n = 66) 
Age (yr) 
<20-40 45 (11%) 30 (9%) 6 (9%) 
40-60 83 (19%) 101 (31%) 23 (35%) 
60- 80 262 (62%) 187 (57%) 34 (51%) 
>-80 34 (8%) 8 (3%) 3 (5%) 
Mean + SD 64 _+ 16 61 _+ 14 61 _+ 13 
Gender 
Male 333 (79%) 125 (38%) 30 (45%) 
Female 91 (21%) 201 (62%) 36 (55%) 
Left atrial size (ram) 
<40 103 (24%) 17 (5%,) 4 (6%) 
40-45 72 (17%) 34 (11%) 7 (11%) 
45-54 91 (21%) 89 (27%) 16 (24%) 
>-55 24 (6%) 108 (33%) 24 (36%) 
Atrial fibrillation 
Preoperative 35 (8%) 178 (55%) 35 (53%) 
Postoperative 50 (12%) 161 (49%) 34 (53%) 
Either 59 (14%) 202 (62%) 40 (61%) 
Thromboembolism 
Preoperative 25 (6%) 59 (18%) 11 (l 7%) 
Unknown 4 (1%) 1 (0.3%) 
Coronary artery disease 
None 166 (39%) 164 (51%) 32 (48%) 
One vessel 65 (15%) 20 (6%) 2 (3%) 
Two vessels 46 (11%) 33 (10%) 3 (5%) 
Three vessels 35 (8%) 14 (4%) 1 (2%) 
No coronary angiography 112 (27%) 95 (29%) 28 (42%) 
NYHA functional c ass 
I 16 (4%) 8 (2%) 2 (3%) 
II 82 (19%) 44 (14%) 5 (8%) 
III 225 (53%) 173 (53%) 28 (42%) 
1V 101 (24%) 101 (31%) 31 (47%) 
Time of surgery 
1975-1977 116 (27%) 132 (41%) 20 (30%) 
1978-1980 121 (29%) 112 (34%) 18 (27%) 
1981-1982 187 (44czc,) 82 (25%) 28 (43%) 
Type of prosthesis 
Hancock 177 (42%)* 182 (56%) 35t (53%) 
Carpentier-Edwards 56 (13%) 90 (28%) 3 (5%) 
Ionescu-Shiley 191 (45%) 54 (16%) 28 (42%) 
Treatment 
Aspirin.?. 105 (25%) 40 (12%) 11 (17%) 
Dipyridamole$ 108 (25%) 76 (23%) 18 (27%) 
Sulfinpyazone 1 (0.2%) 2 (0.6%) 0 
Warfarin started in hospital 144 (34%) 258 (79%) 46 (70%) 
Digoxin started in hospital 248 (58%) 251 (77%) 54 (82%) 
Pts with anticoagulation (% of PT 
<1.3 and <1.5 × control)§ 
At 0-10 days postop 32% (63 and 70) 78% (40 and 52) 70% (49 and 62) 
At 11-90 days postop 35% (36 and 52) 86% (21 and 35) 74% (26 and 42) 
At >90 days postop 37% (48 and 61) 86% (28 and 42) 82% (27 and 45) 
*Two patients (Pts) had a Hancock valve with a conduit from left ventricle to descending aorta, tAll but one patient 
had the same type of prosthesis implanted inboth positions (mitral and aortic). SEver taking aspirin or dipyridamole 
before vent. §Treated uring or before (->1 day), but not in response to, thromboembolic event. Data presented are 
number (%) of patients, unless otherwise indicated. NYHA = New York Heart Association; postop = after operation. 
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Table 2. Postoperative Events 
Valve Replacement 
Aortic Mitral Aortic and Mitral 
(n = 424) (n = 326) (n = 66) 
Thromboembolism 
First 51 (12%) 55 (17%) 6 (9%) 
Second 10 (2%) 13 (4%) I (2%) 
Bleeding events 
First 59 (14%) 41 (13%) 11 (17%) 
Second 13 (3%) 6 (2%) 2 (3%) 
Total deaths 184 (43%) 165 (51%) 36 (55%) 
Cardiac* 87 (21%) 92 (28%) 19 (29%) 
Noncardiac 71 (17%) 41 (13%) 11 (17%) 
Operativet 9 (2%) 11 (3%) 4 (6%) 
Cerebral infarction 5 (1%) 4 (1%) 1 (2%) 
Cerebral hemorrhage 4 (1%) 6 (2%) 1 (2%) 
Systemic emboli 2 (0.5%) 4 (1%) 0 
Hemorrhage 6 (1%) 6 (2%) 0 
Unknown 0 1 (0.2%) 0 
Reoperation 68 (16%) 54 (17%) 17 (26%) 
*38% arrhythmic, 17% ischemic, 43% heart failure, 2% endocarditis, tWithin 30 days of operation. Data presented 
are number (%) of patients. 
artery disease. Those with mitral or double valve replacement 
were predominantly female, presented with larger left atria 
(95% abnormal), had a greater prevalence of atrial fibrillation 
before and after operation and had a higher prevalence 
of previous thromboembolic episodes (18%). Almost 67% of 
patients with mitral valve replacement compared with 33% of 
those with aortic valve replacement were discharged with 
anticoagulation. Aspirin was usually instituted when warfarin 
was discontinued; the median times to starting aspirin were 
134, 253 and 433 days for aortic, mitral and double valve 
replacement, respectively. Dipyridamole was given with warfa- 
rin in 101 patients, with aspirin in 85 and alone in another 14. 
There was a strong correlation between year of operation 
and the type of valve implanted. In the first 4 years of the study 
period, all bioprosthetic valves implanted were Hancock, and 
in the last 2 years the majority (86%) were Ionescu-Shiley. 
Table 2 lists the postoperative thromboembolic and bleeding 
episodes, reoperations and causes of death. During follow-up, 
385 patients (47%) died. Kaplan-Meier survival curves to all 
causes of death for each valve location are shown in Figure 1 
(top); survival curves to cardiac death are shown in Figure 1 
(bottom). Patients with mitral or double valve replacement had 
a greater incidence of cardiac death (p = 0.03) than those with 
aortic valve replacement. 
Thromboembolie episodes. One hundred twelve patients 
(2.3%/year) had one thromboembolic episode, and 24 (6.1%/ 
year after the first episode) had two episodes (Tables 2 and 3). 
Two patients had a neurologic deficit within 24 h of operation 
but are not included as having a thromboembolic episode. 
Table 3 lists the sites of thromboembolism, linearized rates, 
resultant degree of disability and treatment status. Ninety- 
three percent of the emboli went to the brain and retina and 
7% were peripheral. Fifty-eight percent of patients fully recov- 
ered; 38% had a permanent neurologic deficit; and 4% died. 
Only 10%, 44% and 17% of aortic, mitral and double valve 
recipients, respectively, had anticoagulation at the time of the 
event. 
Figure 1. Kaplan-Meier survival curves for death (top) and cardiac 
death (bottom) after valve replacement. 
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Table 3. Site, Outcome and Therapy at Time of First and Second Thromboembolic Events 
Valve Replacement 
Aortic 
First Second 
Mitral Aortic and Mitral 
First Second First Second 
No. of events (%/yr) 51 (2.2) 10 (4.6) 
Total linearized rate (%/yr) 2.2 4.6 
Site (% of total events) 
Cerebral 96% 100% 
Coronary 0 0 
Peripheral 4% 0 
Outcome of cerebral events 
Full recovery 47% 50% 
Permanent defect 53% 40% 
Death 0 10% 
Therapy at event (% of total) 
Warfarin 8% 30% 
Aspirin 25% 20% 
Dipyridamole 25% 40% 
None 41% 10% 
55 (3.1) 13 (5.8) 6 (1.7) 1 (3.7) 
3.1 5.8 1.7 3.7 
89% 85% 6/6* 1/1' 
0 15% 0 0 
11% 0 0 0 
69% 54% 3/6* 0 
24% 38% 2/6* 1/1' 
7% 8% 1/6' 0 
44% 62% 1/6 0 
13% 15% 0 0 
13% 23% 0 1/1' 
30% 0 5/6* 0 
*Expressed as fraction of total patients. 
Figure 2 shows the rates of thromboembolic episodes, with 
and without anticoagulant agents, at the three different inter- 
vals for each valve location. The rate of thromboembolic 
episodes in aortic valve recipients during the first 10 days after 
operation was extremely high in those patients without antico- 
agulation and was significantly higher than that rate at 11 to 90 
days (3.6%/year) and >90 days (1.9%/year) (p < 0.001). In 
mitral valve recipients, the rate during the first 10 days 
(55%~year) was significantly higher than that at 11 to 90 days 
(10%/year) (p < 0.007), and the latter was significantly higher 
than the rate after 90 days (2.4%/year) (p = 0.006). By 
multivariate Cox model analysis, the risk of thromboembolism 
increased with mitral valve location, lack of anticoagulation, 
age and history of thromboembolism (Table 4). Aspirin and 
dipyridamole were also evaluated in this model, and neither 
was associated with a reduced risk of thromboembolism. Valve 
type did not significantly change the risk of thromboembolism. 
Factors not significant in these patients but associated with 
thromboembolism in other studies include atrial fibrillation, 
year of operation, atrial size, presence of coronary artery 
disease and functional class. 
Figure 3 shows the Kaplan-Meier curves for the incidence 
of thromboembolism for each valve location. The probability 
of freedom from a thromboembolic event at 5 years was 89% 
for patients with aortic, 85% for mitral and 95% for double 
valve replacement. 
Bleeding events. One hundred eleven patients (2.3%/year) 
had a bleeding event. Risk factors associated with a bleeding 
event were anticoagulation a d increased age (Table 4). The 
linearized rates of bleeding (%/year) for patients with (with- 
out) anticoagulation were 6.2 (1.6), 2.7 (1.1) and 4.5 (1.9) per 
patient-year for aortic, mitral and double valve replacement, 
respectively. Bleeding sites, complications and treatment a the 
time of the event are presented inTable 5. Fifty-one percent of 
these bleeding events were gastrointestinal. B ood transfusions 
were required in 54% of patients. Of 32 patients with a first 
bleeding event, 13 died as a result of cerebral bleeding, and 
fatal or nonfatal cerebral bleeding occurred in 19. Four 
patients died as a result of a second bleeding event. Kaplan- 
Meier curves for bleeding by valve location were similar (data 
not shown). At 5 years, the probabilities of freedom from a 
bleeding complication were 89%, 89% and 86% for patients 
with aortic, mitral and double valve replacement, respectively. 
Antieoagulation. Table 1 shows the proportion of patients 
treated with anticoagulant agents at each of the three intervals 
before any thromboembolic event (at least 1 day). During the 
first 10 days after operation, 52% to 70% of prothrombin times 
were < 1.5 × control. Patients who had aortic and mitral valve 
replacement and who were treated with anticoagulant agents 
had a similar prevalence of atrial fibrillation, previous throm- 
boembolism and left atrial dimensions to those without anti- 
coagulation. However, mitral valve recipients with anticoagu- 
lation for up to 90 days had a higher prevalence of atrial 
Figure 2. Linearized rates of thromboembolic events by anticoagula- 
tion (AC) status and days after operation. 
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Table 4. Multivariate Cox Analysis 
Thromboembolic Events Bleeding Events 
Variable Coeff SE p Value Coeff SE p Value 
Valve replacement 
Aortic 0.06 0.44 < 0.001 * - 0.11 0.34 NS 
Mitral 058 0.22 < 0.001 * 0.92 0.24 NS 
Double 0.06 0.44 < 0.001 * 0.11 0.34 NS 
Agct 0.02 0.007 0.014 0.04 0.01 
AC 0.66 0.24 0.007 1.11 0.22 
Hx of TE 0.77 0.24 0.002 
*Testing valve location with two degrees offreedom, tAge is centered at the mean value. AC = anticoagulation; 
Coeff. = coefficient; Hxof TE = history, ofthromboembolism. 
fibrillation both before (p < 0.1) and after (p < 0.05) 
operation. 
Only 29 of 112 patients were taking anticoagulant agents at 
the time of their first thromboembolic episode (Table 3). 
Sixty-two f 111 patients were taking anticoagulant agents at 
the time of their first bleeding event. Prothrombin time ratios 
were available in 27 of 62 patients and were <1.5 in 9, between 
1.5 and 2.0 in 9 and >2.0 in 9. 
Discussion 
Thromboembolism. The present study shows a high inci- 
dence of thromboembolic episodes during the first 10 postop- 
erative days for patients with aortic and mitral bioprosthetic 
valve replacement when anticoagulation is either not adminis- 
tered or is subtherapeutic, n part because warfarin therapy is 
started at 48 h and has a delayed onset. The risk of thrombo- 
embolism remained high after mitral valve replacement for at 
least 90 days (10%/year) after operation. Anticoagulation 
significantly decreased the incidence of thromboembolism. On 
the basis of pathogenesis and risk (1), the present data suggest 
that early anticoagulation to stable therapeutic levels and 
maintenance of the prothrombin time ratio at 1.5 to 2.0 
(international normalized ratio 3.0 to 4.5) may be needed for a 
minimum of 3 months. 
Patients with mitral valve replacement had the highest rate 
of thromboembolism, even with anticoagulation during the 
first 10 and 11 to 90 days after operation (48%/year and 
9.9%/year, espectively). Reasons for this may relate to the 
high incidence of left atrial enlargement and atrial fibrillation 
(Table 1) and to three aspects of antithrombotic therapy 
independent ofvalve replacement location. 
First, delay in achieving therapeutic levels of anticoagula- 
tion may result in early, rapid growth of valvular or atrial 
thrombus. Prothrombin times were < 1.5 x control in 70% of 
measurements during the first 10 days after operation. The 
delay may be inherent in the longer half-life of certain vitamin 
K-dependent coagulation factors (especially Factors II, X and 
IX) and the 48-h delay in the start of warfarin administration. 
Substrates for high acute thrombogenicity nclude the valve 
excision site, prosthetic Dacron sewing rings common to all 
prosthetic valves, suture material and xenotropic valvular 
tissue, among other factors usually greater in patients with 
mitral valve replacement (dilated cardiac chambers and de- 
creased cardiac output). 
Second, variable and subtherapeutic prothrombin times 
increase the risk of thromboembolism in patients with pros- 
thetic heart valves. Variability is probably as important as 
intensity (4,8). For example, Sauor et al. (8) reported high and 
similar rates of thromboembolism (4.0 and 3.7%/year) in 
moderate and high intensity anticoagulation groups, respec- 
tively, even though the target prothrombin time ratio was 1.5 _+ 
0.2 (international normalized ratio 2.65) and 2.5 +_ 0.2 (inter- 
national normalized ratio 9.0), respectively. In that study, 19 of 
33 thromboembolic events occurred when the prothrombin 
time ratio (at the time of the event) was <1.5 x control 
(approximately half in each group) (8), which suggests high 
variability in both groups. 
Third, starting warfarin therapy without simultaneous ther- 
apeutic heparin in situations of high thrombotic risk may 
enhance thrombosis (9). Maximal prevention may include 
early anticoagulation with heparin, initiation of oral anticoag- 
ulation on the day of operation and maintenance of interna- 
tional normalized ratio at 3.0 to 4.0 for 3 months, passivation 
of thrombosis on prosthetic or injured cardiac surfaces, plate- 
let inhibitor therapy or a combination of these. Low dose 
aspirin (100 mg/day) combined with warfarin (international 
normalized ratio 3.0 to 4.5) has been successful (10). 
Figure 3. Kaplan-Meier survival curves for first hromboembolic event 
after valve replacement. 
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Table 5. Site of and Therapy for First and Second Bleeding Events 
Valve Replacement 
Aortic Mitral Aortic and Mitral Total 
First Second First Second First Second First Second 
No. of events (%/yr) 59 (2.3) 13 (11.1) 41 (2.1) 6 (4.0) 11 (3.0) 2 (7.4) 111 (2.3) 21 (7.2) 
Site (% of total [%/yr]) 
Cerebral* 12% 0 22% 33% 27% 0 17%t 10% 
Gastrointestinal:~ 56% 85 % 49% 67% 36% 50% 51% 76% 
Urinary 15% 15% 5% 0 9% 50% 11% 14% 
Epistaxis 0 0 2% 0 0 0 1% 0 
Other 17% 0 22% 0 27% 0 20% 0 
Transfusion (% of total events [%/yr]) 32% 69% 44% 67% 64% 50% 54% (1.2) 67% 
Therapy at event 
Anticoagulation 39% 23% 78% 83% 64% 50% 56% 43% 
Aspirin 29% 46% 5% 0 9% 0 18% 29% 
Neither 32% 31% 17% 17% 27% 50% 26% 29% 
Death (% of total [%/yr]) 8% 15% 20% 33% 0 0 12% (0.3) 19% 
*Four of seven of aortic, nine of nine mitral and two of three double valve recipients had anticoagulation at time of event. ]13 fatal and 6 nonfatal = 19/111 (17%). 
:~18% of aortic, 70% of mitral and two of four double valve recipients had anticoagulation at time of event. 
Short-term anticoagulation in all patients for 2 to 3 months 
after operation has resulted in very low rates of thromboem- 
bolism (11). This group (A. F. Carpentier, personal communi- 
cation, January 1994) also starts a heparin infusion -6  h after 
operation to mildly prolong the activated partial thromboplas- 
tin time to slightly above the upper limit of normal; after chest 
tubes have been removed, heparin is increased to an activated 
partial thromboplastin time of 1.5 to 2.0 times control. Oral 
anticoagulation is started when patients resume oral intake, 
and heparin infusion is continued until the prothrombin time 
has been in the therapeutic range for 2 days. 
Our thromboembolism rates for patients with aortic, mitral 
and combined valve replacement are higher than those re- 
ported by Hartz et al. (12), Zussa et al. (13) and Reul et al. 
(14). Inclusion of stroke, transient cerebral ischemia and 
coronary and peripheral artery thromboembolism; questioning 
of both patients and physicians by letter and telephone for 
thromboembolic events; and review of local hospital records 
for patients readmitted to the hospital may account for our 
higher rates. The low rates of thromboembolism (although 
higher with atrial fibrillation) reported by Oyer et al. (15) may 
be explained by anticoagulation i all patients for 6 weeks. 
Spencer et al. (16) documented a similar survival free of 
thromboembolism for patients with aortic and mitral valve 
replacement. 
Approximately 90% of the emboli clinically affected the 
brain or retina, the most sensitive organs for symptomatic 
detection. It is likely that some peripheral thromboembolic 
episodes went undetected; therefore, the true embolic rate is 
probably higher. Emboli caused permanent disability or death 
in 42% of patients; this rate is very similar to those in 
previously reported series of younger patients with older 
mechanical valves (17,18). 
Although patients with double valve replacement had the 
lowest rates of thromboembolism, the overall incidence in this 
small (also nonrandomized) group was not statistically differ- 
ent from that in patients with mitral or aortic valve replace- 
ment. Lower rates of thromboembolism for multivalve than 
mitral valve replacement have also been reported by Gallo et 
al. (19) and Zussa et al. (13), although their patients had 
anticoagulation for at least 3 months. 
Multivariate analysis. Of the variables analyzed in the 
multivariate Cox analysis, valve location, history of thrombo- 
embolism, increasing age and lack of treatment with anticoag- 
ulant agents were predictive of thromboembolism. Patients 
with aortic valve replacement had the lowest estimated risk, 
whereas those with mitral valve replacement had the highest. 
Patients with anticoagulation are estimated to have a lower risk 
than those with no treatment. In our retrospective study, the 
finding that aspirin did not show a beneficial effect does not 
confirm previous retrospective findings that aspirin alone may 
be sufficient o prevent hromboembolic episodes in patients 
with bioprostheses (20-23). Treatment with dipyridamole also 
did not reduce the incidence of thromboembolism. 
None of the other known risk factors examined, such as 
atrial fibrillation or left atrial size, were significant predictors 
of increased risk; however, one of these risk factors was 
present in >90% of patients with mitral valve replacement. 
Sixty-one percent of mitral and combined bioprosthetic valve 
recipients had atrial fibrillation before or after operation, and 
<10% had normal-sized left atria. Left atrial size, age >60 
years, possible left ventricular dysfunction and even hyperten- 
sion under treatment all add risk for thromboembolism in 
patients with atrial fibrillation (24-26). This high overall 
incidence of risk may account in part for the high rates of 
thromboembolism in the present study. 
Bleeding. The rates of bleeding in our series are slightly 
higher than those previously reported (16,27,28), perhaps 
because we recorded all bleeding episodes regardless of anti- 
coagulation status. Other studies analyzed only bleeding sec- 
ondary to warfarin and aspirin treatment, but as shown in the 
present multivariate analysis, age is a very important risk factor 
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for bleeding independent of anticoagulant or antiplatelet 
therapy. At the time of bleeding, 56% of patients were taking 
warfarin, 18% were treated with aspirin. Therefore, the risk of 
bleeding increased with age and treatment with anticoagulants. 
Bleeding events were independent of valve location. The 
higher ates of bleeding observed in the aortic valve recipients 
may reflect their older age. 
Study limitations. This was a retrospective study. Antico- 
agulation or antiplatelet therapy, or both, was not randomized. 
However, follow-up and thromboembolic and bleeding event 
information were obtained for all but two patients. Although 
we know when patients were taking warfarin, complete quan- 
titative data on prothrombin times >90 days after operation 
were insufficient to address completely the adequacy of long- 
term anticoagulation. Therefore, all analyses were based on 
the presence or absence of medical treatment. In addition, 
there were no data for left atrial size (Table 1) because 
echocardiographic studies were not performed in the early 
patients in this study. 
Conclusions. Patients with bioprosthetic aortic or mitral 
valve replacement have a high risk of thromboembolism during 
the first 10 days, high (mitral) to medium (aortic) risk at 11 to 
90 days after operation and medium (mitral) to low (aortic) 
risk thereafter. Strategies for prevention should be based on 
pathogenesis and risk of thrornboembolism (1). 
Because of the high incidence of thromboembolism, all
patients with bioprostheses may benefit from early anticoagu- 
lation with heparin starting 6 h after operation to prolong 
activated partial thromboplastin time to slightly above the 
upper limit of normal, an increase to an activated partial 
thromboplastin time of 1.5 to 2.0 x control 6 h after chest 
tubes are removed, oral low dose aspirin (80 to 100 nag) 48 h 
after operation and oral anticoagulation starting the night 
before operation (29) for 3 months after operation (4) at an 
international normalized ratio of 3.0 to 3.5. Those with risk 
factors (atrial fibrillation, enlarged left atrium or notable left 
ventricular dysfunction) should receive long-term anticoagula- 
tion at an international normalized ratio of 2.0 to 3.0 regardless 
of valve location(s). Thus, aortic valve recipients and mitral 
valve recipients with reversible or no risk factors may be able 
to avoid long-term anticoagulation, but patients >60 years old 
have a risk of 4.6%/yr of myocardial infarction, stroke or 
vascular death and thus probably should receive daily aspirin. 
High risk patients with concomitant coronary artery bypass 
grafting or vascular disease should probably also receive low 
dose aspirin in addition to warfarin, in keeping with the 
prospective study of Turpie et al. (10). Older patients are at a 
higher isk for both thromboembolic and bleeding episodes; in 
this group, a careful selection of patients at high risk for 
thromboembolism and strict control of anticoagulation a d 
blood pressure (<150/90 mm Hg, perhaps with beta- 
adrenergic blocking agent herapy to decrease pulse pressure) 
may diminish bleeding complications while preventing throm- 
boembolism. These therapeutic strategies currently appear 
prudent but need testing in a prospective, randomized study. 
We greatly appreciate he skillful and dedicated work of Kim D. Jones in patient 
follow-up and the secretarial help of Amy Pelot, Mary Boecker and Flo Lue. 
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